January 17, 2017
Sanofi’s new insuline combination of Saliqua cleared for Europe
The European Commission has cleared Sanofi’s Suliqua in combination with metformin, type 2 diabetes treatment, for European adult patients.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
January 17, 2017
Biogen settles to pay Danish Forward $1.25 bilion
Danish biopharmaceutical company, Forward Pharma, has entered a deal with Biogen and certain other parties, regarding a Settlement and License Agreement.
January 17, 2017
BD Precise WTA kits for single cell research available for sale
Becton, Dickinson’s (BD’s) new kits that provide an easier method to identify and quantify genetic information in individual cells for genomics-based research, have started selling.
January 17, 2017
Allergan, Gedeon Richter report positive results from uterine fibroids drug trial
Allergan and Gedeon Richter have reported positive results from Venus II, the second of two pivotal phase III clinical trials…
January 17, 2017
Pharnext wins Best Life-Scineces IPO France 2016 Award
Pharnext, a French biopharmaceutical company focused on drugs against neurodegenerative diseases, has been named Best Life-Sciences IPO France 2016 Award.
January 17, 2017
Dechra’s acquisitions deliver good half year results
Dechra has issued an unaudited Trading Update covering the half year reporting period (the Period) from 1 July to 31…
January 17, 2017
Oxford Pharmascience studies/regulatory update for OXPzero, looks for potential partners
Oxford Pharmascience Group has completed laboratory work to identify modifications to the OXPzero technology platform that alter the release properties and enable faster release of the NSAID.
January 17, 2017
Bavarian Nordic appoints Henrik Birk as COO
Bavarian Nordic has appointed Henrik Birk as Chief Operating Officer, the newly created position where he will develop and lead the execution of Bavarian Nordic’s operational and HR strategies.
January 17, 2017
Onzima buys remaining 51% of N4 Pharma
Onzima Ventures said on Tuestday it would buy another 51% of N4 Pharma Limited shares with 34609210 new ordinary shares of of 0.1p each in its capital. The acquisition should be completed by mid-April 2017.
January 17, 2017
Sinclair tops out market expectations, sales rise 37%
Pure-play aesthetics company SInclair Pharma has reported topping out market expectations with sales in the twelve months until December 2016 being about £2m, which represents the gorwth of more than 37% to £37.8m.